IGC Pharma Inc
Research IGC Pharma Inc (IGC) on Bullrun: market cap USD 30.03M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIGC
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 30.03M
- Financial periodQ1 2026
- RevenueUSD 317.00K
- Net income-USD 2.40M
- Free cash flow-USD 1.39M
- Gross margin17.4%
Valuation Snapshot
latest market cap is USD 30.03M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.27M | -USD 7.12M | -USD 4.91M | 48.7% | -0.09 | USD 405.00K | USD 137.00K | USD 6.33M |
| FY2024 | USD 1.35M | -USD 13.00M | -USD 5.34M | 54.5% | -0.22 | USD 1.20M | USD 140.00K | USD 7.32M |
| FY2023 | USD 911.00K | -USD 11.51M | -USD 7.36M | 48.5% | n/a | USD 3.20M | USD 144.00K | USD 14.91M |
| FY2022 | USD 397.00K | -USD 15.02M | -USD 7.70M | 48.9% | n/a | USD 10.46M | USD 147.00K | USD 23.89M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 30.03M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 26.61M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 26.59M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 17.85M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 16.98M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 50.03M | n/a | n/a | n/a |
About IGC Pharma Inc
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is IGC Pharma Inc's market cap?
IGC Pharma Inc's market capitalization is USD 30.03M.
What does IGC Pharma Inc do?
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers.